Inclusion Criteria:

- Subjects undergoing curative surgical resection for cholangiocarcinoma (including
cancer of the gallbladder [except stage I], intrahepatic, and extrahepatic bile duct)

- Histological confirmation is mandatory.

- Age over 18 years old

- Performance status (ECOG scale): 0-2

- Adequate organ functions Hb ≥ 9.0 g/dl ANC: ≥ 1,500/mm3 PLT ≥ 100,000 /mm3 Liver
function: Total Bilirubin ≤ 2.0 mg/dl AST / ALT / ALP ≤ 3× upper limit of normal
Creatinine ≤ 1.5 ULN

- Patients should sign a written informed consent before study entry.

Exclusion Criteria:

- Tumor type other than adenocarcinoma

- Stage I gallbladder cancer

- Noncurative surgical resection including R2 resection

- Other primary malignancy (except in situ carcinoma of the cervix or adequately
treated basal cell carcinoma of the skin or prior malignancy treated more than 5
years ago without recurrence)

- Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive
immunotherapy)

- Prior radiotherapy

- Major surgery within 4 weeks prior to study treatment except for surgical resection
of cholangiocarcinoma

- Serious illness or medical conditions, as follows; congestive heart failure (NYHA
class III or IV) unstable angina or myocardial infarction within the past 6 months,
significant arrhythmias requiring medication and conduction abnormality such as over
2nd degree AV block uncontrolled hypertension hepatic cirrhosis(≥ Child class B)
interstitial pneumonia, pulmonary adenomatosis psychiatric disorder that may
interfere with and/or protocol compliance unstable diabetes mellitus uncontrolled
ascites or pleural effusion active infection

- Received any investigational drug or agent/procedure, i.e. participation in another
trial within 4 weeks before beginning treatment with study drug

- Pregnant or lactating woman

- Women of child bearing potential not using a contraceptive method

- Sexually active fertile men not using effective birth control during medication of
study drug and up to 6 months after completion of study drug if their partners are
women of child-bearing potential

- Any patients judged by the investigator to be unfit to participate in the study